Subscribe to these results:

Upcoming Workshops

For Bladder Cancer

  1. Register

For Brain Cancer

  1. Register

For Breast Cancer

  1. Register
  2. Register
  3. Register

For Cervical Cancer

  1. Register

For Head and Neck Cancer

  1. Register

For Kidney Cancer

  1. Register

For Leukemia

  1. Register

For Lung Cancer

  1. Register

For Mantle Cell Lymphoma

  1. Register

For Multiple Myeloma

  1. Register

For Prostate Cancer

  1. Register

For Skin Cancer

  1. Register

For Uterine Cancer

  1. Register

Past workshops

For All Cancers

    1. Understanding Diagnostic Technologies and Biomarkers
    2. Chemotherapy Treatment Side Effects: Prevention & Management
    3. Diverse Populations Participating in Decisions about Your Care with Your Health Care TeamPart II of How Health Care Disparities May Influence Your Cancer Treatment and Care
    4. Clinical Trials: How They Transform the Treatment of Cancer
    5. Managing the Side Effects of ImmunotherapyPart II of New Trends in Immunotherapy
    6. Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
    7. Understanding How Health Care Disparities May Influence Your Cancer Treatment and Care: With Tips & Strategies to Find the Best Cancer Treatment & Health Care Team for YouPart I of How Health Care Disparities May Influence Your Cancer Treatment and Care
    8. CAR T-Cell Therapy: What's New
    9. Preventing, Managing & Treating Infection in Adults Living with Cancer
    10. What’s New in Precision Medicine
    11. How Health Care Disparities May Influence Your Cancer Treatment & Care
    12. Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
    13. Taking Your Pills on Schedule: Why It Is So Important in Managing Cancer
    14. Emerging Importance of Telemedicine/Telehealth Appointments in Communicating with Your Health Care Team
    15. Cancer and Flu Shots
    16. Treatment Adherence: Taking Your Pills on Schedule – Why It Is So Important
    17. What are Biosimilars? Understanding Their Role in Cancer Treatment: Current and Future Perspectives
    18. Managing the Side Effects of ImmunotherapyPart II of New Trends in Immunotherapy
    19. Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
    20. Participating in Decisions about Your CarePart IV of Life with Cancer: A Guide to Getting the Best Care
    21. Understanding the Costs of Care and Your Health Care CoveragePart II of Life with Cancer: A Guide to Getting the Best Care
    22. Taking Your Treatment on Schedule: Its Importance in Managing Cancer
    23. Care for Your Bones During & After Cancer Treatment: Tips to Improve Bone Health
    24. Participating in Decisions about Your CarePart V of Life with Cancer: A Guide to Getting the Best Care
    25. Medical Emergencies in Cancer Treatment

For Acute Lymphoblastic Leukemia

    1. Update from the 2022 American Society of Hematology (ASH) Annual Meeting
    2. Chronic Lymphocytic Leukemia (CLL): Treatment Updates
    3. New Treatments for Childhood Acute Lymphocytic Leukemia (ALL)
    4. Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
    5. Adults Living with Acute Lymphocytic Leukemia (ALL): Treatment Updates
    6. Progress in the Treatment of Myelodysplastic Syndromes (MDS)
    7. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    8. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    9. What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
    10. Update from the 2021 American Society of Hematology (ASH) Annual Meeting
    11. Transplantation as a Treatment Option for Blood Cancers
    12. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    13. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    14. Updates from the 2020 American Society of Hematology (ASH) Annual Meeting
    15. Update on CAR-T Cell Therapy
    16. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    17. Taking Your Blood Cancer Treatment on Schedule
    18. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    19. Treatment Update for Adults Living with Acute Lymphocytic Leukemia (ALL)
    20. New Treatments for Childhood Acute Lymphocytic Leukemia (ALL)

For Acute Myeloid Leukemia

    1. Update from the 2022 American Society of Hematology (ASH) Annual Meeting
    2. Chronic Lymphocytic Leukemia (CLL): Treatment Updates
    3. Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
    4. Adults Living with Acute Lymphocytic Leukemia (ALL): Treatment Updates
    5. Progress in the Treatment of Myelodysplastic Syndromes (MDS)
    6. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    7. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    8. Acute Myeloid Leukemia (AML): Treatment Updates
    9. What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
    10. Update from the 2021 American Society of Hematology (ASH) Annual Meeting
    11. Transplantation as a Treatment Option for Blood Cancers
    12. Update on the Treatment of Acute Myelogenous Leukemia (AML)
    13. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    14. Update on CAR T-Cell Therapies
    15. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    16. Updates from the 2020 American Society of Hematology (ASH) Annual Meeting
    17. Living with Acute Myelogenous Leukemia (AML)
    18. Update on CAR-T Cell Therapy
    19. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    20. Taking Your Blood Cancer Treatment on Schedule
    21. Updates in the Treatment of Acute Myelogenous Leukemia
    22. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches

For Basal Cell Cancer

    1. New Perspectives in the Treatment of Advanced Skin Cancer: Advanced Basal Cell and Squamous Cell Cancers
    2. New Perspectives in the Treatment of Advanced Skin Cancer: Advanced Basal Cell and Squamous Cell CancersPart I of Life with Advanced Skin Cancer

For Bladder Cancer

    1. Bladder Cancer: Treatment UpdatePart I of Life with Bladder Cancer
    2. Bladder Cancer: Treatment UpdatesPart I of Life with Bladder Cancer
    3. Update on the Treatment of Bladder CancerPart I of Living with Bladder Cancer
    4. What’s New in the Treatment of Bladder CancerPart I of Life with Bladder Cancer
    5. Updates on the Treatment of Bladder Cancer

For Bone Cancer

    1. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches

For Brain Cancer

    1. Highlights from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting – “Advancing Equitable Cancer Care Through Innovation"Part I of Highlights from the 2022 ASCO Annual Meeting
    2. Glioblastoma in Adults: Treatment Updates
    3. Update on Glioblastoma in Adults
    4. Highlights from the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting: Unite and Conquer: Accelerating Progress TogetherPart I of Your Guide to the Latest Cancer Research and Treatment
    5. Update on Glioblastoma in Adults

For Breast Cancer

    1. Updates from the 45th Annual San Antonio Breast Cancer Symposium on Triple Negative Breast Cancer
    2. Living with Breast Cancer – Updates from the 45th San Antonio Breast Cancer Symposium (SABCS)Part I of Living with Breast Cancer – Updates from the 45th Annual San Antonio Breast Cancer Symposium (SABCS)
    3. The Benefits of Clinical Trials for Triple Negative Breast Cancer
    4. Metastatic Triple Negative Breast CancerPart I of Living with Metastatic Triple Negative Breast Cancer
    5. Metastatic Breast Cancer: Treatment Updates
    6. Highlights from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting – “Advancing Equitable Cancer Care Through Innovation"Part I of Highlights from the 2022 ASCO Annual Meeting
    7. HER2-Positive Metastatic Breast Cancer: What’s New in Treatment & Quality-of-Life
    8. The Role of Radiation Therapy in the Treatment of Breast Cancer
    9. Metastatic Breast Cancer in African Americans: New Treatments
    10. Updates in the Treatment of Estrogen Receptor (ER) Positive, Progesterone Receptor (PR) Positive and HER2 Positive Breast Cancer from the San Antonio Breast Cancer Symposium (SABCS)Part II of Living with Breast Cancer, with Updates from the San Antonio Breast Cancer Symposium (SABCS)
    11. Updates from the 44th Annual San Antonio Breast Cancer Symposium (SABCS) on Triple Negative Breast Cancer (TNBC)
    12. The Latest Developments Reported at the 44th Annual San Antonio Breast Cancer Symposium (SABCS)Part I of Living with Breast Cancer, with Updates from the San Antonio Breast Cancer Symposium (SABCS)
    13. Triple Negative Breast Cancer and African American Women
    14. HER2-Positive Metastatic Breast Cancer: New Therapies
    15. Metastatic Breast Cancer: Treatment Updates
    16. Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart I of Equity. Every Patient. Every Day. Everywhere.
    17. Updates on the Treatment of Estrogen Receptor (ER) Positive, Progesterone Receptor (PR) Positive & HER2 Positive Breast Cancer from the 43rd Annual San Antonio Breast Cancer Symposium (SABCS)Part II of Life with Breast Cancer - Updates from the 43rd Annual San Antonio Breast Cancer Symposium (SABCS)
    18. The Latest Developments Reported from the 43rd Annual San Antonio Breast Cancer Symposium (SABCS)Part I of Life with Breast Cancer - Updates from the 43rd Annual San Antonio Breast Cancer Symposium (SABCS)
    19. Updates from the San Antonio Breast Cancer Symposium (SABCS) on Triple Negative Breast Cancer (TNBC)
    20. Highlights from the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting: Unite and Conquer: Accelerating Progress TogetherPart I of Your Guide to the Latest Cancer Research and Treatment
    21. Triple Negative Breast Cancer and African American Women
    22. What’s New in the Treatment of Breast Cancer for Women of All Ages
    23. What’s New in the Treatment of Metastatic Breast Cancer

For Cervical Cancer

    1. Highlights from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting – “Advancing Equitable Cancer Care Through Innovation"Part I of Highlights from the 2022 ASCO Annual Meeting
    2. Cervical Cancer: Treatment Advances

For Chronic Lymphocytic Leukemia

    1. Update from the 2022 American Society of Hematology (ASH) Annual Meeting
    2. Chronic Lymphocytic Leukemia (CLL): Treatment Updates
    3. Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
    4. Adults Living with Acute Lymphocytic Leukemia (ALL): Treatment Updates
    5. Progress in the Treatment of Myelodysplastic Syndromes (MDS)
    6. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    7. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    8. Chronic Lymphocytic Leukemia: Current Treatment PerspectivesPart II of Living with Chronic Lymphocytic Leukemia
    9. Chronic Lymphocytic Leukemia: What's NewPart I of Living with Chronic Lymphocytic Leukemia
    10. What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
    11. Update from the 2021 American Society of Hematology (ASH) Annual Meeting
    12. Transplantation as a Treatment Option for Blood Cancers
    13. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    14. Update on CAR T-Cell Therapies
    15. Current Perspectives on the Treatment of Chronic Lymphocytic Leukemia (CLL)Part II of Living with Chronic Lymphocytic Leukemia (CLL)
    16. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    17. Update on Chronic Lymphocytic Leukemia (CLL)Part I of Living with Chronic Lymphocytic Leukemia (CLL)
    18. Updates from the 2020 American Society of Hematology (ASH) Annual Meeting
    19. Update on CAR-T Cell Therapy
    20. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    21. Current Perspectives on the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)Part II of Life with Chronic Lymphocytic Leukemia (CLL)
    22. Update on Chronic Lymphocytic LeukemiaPart I of Life with Chronic Lymphocytic Leukemia (CLL)
    23. Taking Your Blood Cancer Treatment on Schedule
    24. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    25. Life with CLL: Taking Charge of Your Treatment SchedulePart II of Life with Chronic Lymphocytic Leukemia (CLL)

For Chronic Myelogenous Leukemia

    1. Update from the 2022 American Society of Hematology (ASH) Annual Meeting
    2. Chronic Lymphocytic Leukemia (CLL): Treatment Updates
    3. Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
    4. Adults Living with Acute Lymphocytic Leukemia (ALL): Treatment Updates
    5. Progress in the Treatment of Myelodysplastic Syndromes (MDS)
    6. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    7. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    8. What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
    9. Update from the 2021 American Society of Hematology (ASH) Annual Meeting
    10. Transplantation as a Treatment Option for Blood Cancers
    11. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    12. Update on CAR T-Cell Therapies
    13. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    14. Updates from the 2020 American Society of Hematology (ASH) Annual Meeting
    15. Living with Chronic Myelogenous Leukemia (CML)
    16. Update on CAR-T Cell Therapy
    17. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    18. Taking Your Blood Cancer Treatment on Schedule
    19. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches

For Colorectal Cancer

    1. Advances in the Treatment of Colorectal Cancer
    2. Highlights from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - "Advancing Equitable Cancer Care Through Innovation"Part II of Highlights from the 2022 ASCO Annual Meeting
    3. Colorectal Cancer Treatment: Progress and Advances
    4. Colorectal Cancer Treatment: Progress & Advances
    5. Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart II of Equity. Every Patient. Every Day. Everywhere.
    6. Advances in the Treatment of Colorectal Cancer
    7. Progress in the Treatment of Colorectal Cancer

For Cutaneous T-Cell Lymphoma

    1. Diffuse Large B-Cell Lymphoma (DLBCL): Treatment Updates
    2. Update from the 2022 American Society of Hematology (ASH) Annual Meeting
    3. Update On Marginal Zone Lymphoma (MZL)
    4. Waldenstrom’s Macroglobulinemia (WM): Treatment Progress
    5. Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
    6. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    7. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    8. What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
    9. Update from the 2021 American Society of Hematology (ASH) Annual Meeting
    10. Transplantation as a Treatment Option for Blood Cancers
    11. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    12. Update on Diffuse Large B-Cell Lymphoma (DLBCL)
    13. Update on CAR T-Cell Therapies
    14. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    15. Updates from the 2020 American Society of Hematology (ASH) Annual Meeting
    16. Update on CAR-T Cell Therapy
    17. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    18. Taking Your Blood Cancer Treatment on Schedule
    19. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    20. The Emerging Role of Immunotherapy in the Treatment of Lymphoma

For Diffuse Large B-Cell Lymphoma

    1. Diffuse Large B-Cell Lymphoma (DLBCL): Treatment Updates
    2. Update from the 2022 American Society of Hematology (ASH) Annual Meeting
    3. Update On Marginal Zone Lymphoma (MZL)
    4. Waldenstrom’s Macroglobulinemia (WM): Treatment Progress
    5. Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
    6. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    7. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    8. Diffuse Large B-Cell Lymphoma (DLBCL) Updates
    9. What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
    10. Update from the 2021 American Society of Hematology (ASH) Annual Meeting
    11. Update on Diffuse Large B-Cell Lymphoma (DLBCL)
    12. Update on CAR T-Cell Therapies
    13. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    14. Updates from the 2020 American Society of Hematology (ASH) Annual Meeting
    15. Update on Diffuse Large B-Cell Lymphoma (DLBCL)
    16. Update on CAR-T Cell Therapy
    17. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    18. Taking Your Blood Cancer Treatment on Schedule
    19. Update on Diffuse Large B-Cell Lymphoma
    20. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    21. The Emerging Role of Immunotherapy in the Treatment of Lymphoma

For Endometrial Cancer

    1. Update on the Treatment of Endometrial Cancer

For Follicular Lymphoma

    1. Diffuse Large B-Cell Lymphoma (DLBCL): Treatment Updates
    2. Update from the 2022 American Society of Hematology (ASH) Annual Meeting
    3. Update On Marginal Zone Lymphoma (MZL)
    4. Waldenstrom’s Macroglobulinemia (WM): Treatment Progress
    5. Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
    6. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    7. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    8. Follicular Lymphoma: Treatment Progress
    9. What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
    10. Update from the 2021 American Society of Hematology (ASH) Annual Meeting
    11. Transplantation as a Treatment Option for Blood Cancers
    12. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    13. Update on Diffuse Large B-Cell Lymphoma (DLBCL)
    14. Update on CAR T-Cell Therapies
    15. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    16. Progress in the Treatment of Follicular Lymphoma
    17. Updates from the 2020 American Society of Hematology (ASH) Annual Meeting
    18. Update on CAR-T Cell Therapy
    19. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    20. Taking Your Blood Cancer Treatment on Schedule
    21. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    22. The Emerging Role of Immunotherapy in the Treatment of Lymphoma

For Gastric Cancer

    1. Gastric Cancer: Treatment Advances
    2. Gastric Cancer: Treatment Advances
    3. Gastric Cancer: Treatment Updates
    4. Advances in the Treatment of Gastric Cancer
    5. Advances in the Treatment of Gastric Cancer
    6. Current Perspectives in the Treatment of Metastatic Gastric Cancer

For Gastrointestinal Stromal Tumors

    1. Gastric Cancer: Treatment Advances
    2. Gastric Cancer: Treatment Advances
    3. Advances in the Treatment of Gastrointestinal Stromal Tumors (GIST)

For Glioblastoma

    1. Highlights from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting – “Advancing Equitable Cancer Care Through Innovation"Part I of Highlights from the 2022 ASCO Annual Meeting
    2. Glioblastoma in Adults: Treatment Updates
    3. Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart I of Equity. Every Patient. Every Day. Everywhere.
    4. Update on Glioblastoma in Adults
    5. Highlights from the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting: Unite and Conquer: Accelerating Progress TogetherPart I of Your Guide to the Latest Cancer Research and Treatment
    6. Update on Glioblastoma in Adults

For Head and Neck Cancer

    1. Oral, Head & Neck Cancer: Treatment Update
    2. Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart I of Equity. Every Patient. Every Day. Everywhere.
    3. Treatment Update in Oral and Head and Neck Cancer
    4. Highlights from the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting: Unite and Conquer: Accelerating Progress TogetherPart I of Your Guide to the Latest Cancer Research and Treatment
    5. What’s New in the Treatment of Oral and Head and Neck Cancer

For Hodgkin Lymphoma

    1. Diffuse Large B-Cell Lymphoma (DLBCL): Treatment Updates
    2. Update from the 2022 American Society of Hematology (ASH) Annual Meeting
    3. Update On Marginal Zone Lymphoma (MZL)
    4. Waldenstrom’s Macroglobulinemia (WM): Treatment Progress
    5. Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
    6. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    7. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    8. What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
    9. Update from the 2021 American Society of Hematology (ASH) Annual Meeting
    10. Transplantation as a Treatment Option for Blood Cancers
    11. Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
    12. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    13. Update on Diffuse Large B-Cell Lymphoma (DLBCL)
    14. Update on CAR T-Cell Therapies
    15. Progress in the Treatment of Waldenstrom’s Macroglobulinemia (WM)
    16. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    17. Updates from the 2020 American Society of Hematology (ASH) Annual Meeting
    18. What’s New in the Treatment of Hodgkin Lymphoma
    19. Update on CAR-T Cell Therapy
    20. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    21. Taking Your Blood Cancer Treatment on Schedule
    22. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    23. The Emerging Role of Immunotherapy in the Treatment of Lymphoma

For Kidney Cancer

    1. Renal Cell Cancer: Treatment Advances
    2. Advances in the Treatment of Renal Cell Cancer

For Leukemia

    1. Update from the 2022 American Society of Hematology (ASH) Annual Meeting
    2. Chronic Lymphocytic Leukemia (CLL): Treatment Updates
    3. Highlights from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - "Advancing Equitable Cancer Care Through Innovation"Part II of Highlights from the 2022 ASCO Annual Meeting
    4. New Treatments for Childhood Acute Lymphocytic Leukemia (ALL)
    5. Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
    6. Adults Living with Acute Lymphocytic Leukemia (ALL): Treatment Updates
    7. Progress in the Treatment of Myelodysplastic Syndromes (MDS)
    8. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    9. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    10. Acute Myeloid Leukemia (AML): Treatment Updates
    11. Chronic Lymphocytic Leukemia: Current Treatment PerspectivesPart II of Living with Chronic Lymphocytic Leukemia
    12. Chronic Lymphocytic Leukemia: What's NewPart I of Living with Chronic Lymphocytic Leukemia
    13. What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
    14. Update from the 2021 American Society of Hematology (ASH) Annual Meeting
    15. Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart II of Equity. Every Patient. Every Day. Everywhere.
    16. Transplantation as a Treatment Option for Blood Cancers
    17. Progress in the Treatment of Myelofibrosis
    18. Update on the Treatment of Acute Myelogenous Leukemia (AML)
    19. Update on CAR T-Cell Therapies
    20. Current Perspectives on the Treatment of Chronic Lymphocytic Leukemia (CLL)Part II of Living with Chronic Lymphocytic Leukemia (CLL)
    21. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    22. Update on Chronic Lymphocytic Leukemia (CLL)Part I of Living with Chronic Lymphocytic Leukemia (CLL)
    23. Updates from the 2020 American Society of Hematology (ASH) Annual Meeting
    24. Living with Acute Myelogenous Leukemia (AML)
    25. Progress in the Treatment of Myelodysplastic Syndrome (MDS)
    26. Living with Chronic Myelogenous Leukemia (CML)
    27. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    28. Current Perspectives on the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)Part II of Life with Chronic Lymphocytic Leukemia (CLL)
    29. Update on Chronic Lymphocytic LeukemiaPart I of Life with Chronic Lymphocytic Leukemia (CLL)
    30. Taking Your Blood Cancer Treatment on Schedule
    31. Updates in the Treatment of Acute Myelogenous Leukemia
    32. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    33. Treatment Update for Adults Living with Acute Lymphocytic Leukemia (ALL)
    34. Life with CLL: Taking Charge of Your Treatment SchedulePart II of Life with Chronic Lymphocytic Leukemia (CLL)
    35. New Treatments for Childhood Acute Lymphocytic Leukemia (ALL)

For Liver Cancer

    1. Liver Cancer: Treatment Updates
    2. Liver Cancer: Treatment Updates
    3. Treatment Update on Liver Cancer

For Lung Cancer

    1. Highlights from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - "Advancing Equitable Cancer Care Through Innovation"Part II of Highlights from the 2022 ASCO Annual Meeting
    2. Genomic Testing and Current Trends in the Treatment of Non-Small Cell Lung CancerPart III of Living with Non-Small Cell Lung Cancer
    3. Small Cell Lung Cancer: Treatment UpdatePart I of Living with Small Cell Lung Cancer
    4. Non-Small Cell Lung Cancer: Treatment AdvancesPart I of Living with Non-Small Cell Lung Cancer
    5. Non-Small Cell Lung Cancer: What’s NewPart I of Living with Non-Small Cell Lung Cancer
    6. Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart II of Equity. Every Patient. Every Day. Everywhere.
    7. Diverse Populations Living with Non-Small Cell Lung Cancer
    8. Advances in the Treatment of Lung CancerPart I of Living with Lung Cancer
    9. Update on Small Cell Lung Cancer Treatments
    10. For Caregivers: Practical Tips for Coping with Your Loved One’s Lung CancerPart II of Living with Lung Cancer
    11. Progress in the Treatment of Lung CancerPart I of Living with Lung Cancer
    12. Advances in the Treatment of Lung CancerPart I of Life with Lung Cancer
    13. For Caregivers: Practical Tips for Coping with Your Loved One’s Lung Cancer During the HolidaysPart II of Life with Lung Cancer
    14. Progress in the Treatment of Lung CancerPart I of Life with Lung Cancer

For Lymphoma

    1. Diffuse Large B-Cell Lymphoma (DLBCL): Treatment Updates
    2. Update from the 2022 American Society of Hematology (ASH) Annual Meeting
    3. Highlights from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - "Advancing Equitable Cancer Care Through Innovation"Part II of Highlights from the 2022 ASCO Annual Meeting
    4. Update On Marginal Zone Lymphoma (MZL)
    5. Waldenstrom’s Macroglobulinemia (WM): Treatment Progress
    6. Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
    7. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    8. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    9. Mantle Cell Lymphoma: Treatment UpdatePart I of Living with Mantle Cell Lymphoma (MCL)
    10. Follicular Lymphoma: Treatment Progress
    11. Diffuse Large B-Cell Lymphoma (DLBCL) Updates
    12. Marginal Zone Lymphoma (MZL): Treatment Updates
    13. What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
    14. Update from the 2021 American Society of Hematology (ASH) Annual Meeting
    15. Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart II of Equity. Every Patient. Every Day. Everywhere.
    16. Transplantation as a Treatment Option for Blood Cancers
    17. Update on Marginal Zone Lymphoma (MZL)
    18. Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
    19. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    20. Update on Diffuse Large B-Cell Lymphoma (DLBCL)
    21. Update on CAR T-Cell Therapies
    22. Progress in the Treatment of Waldenstrom’s Macroglobulinemia (WM)
    23. Treatment Update on Mantle Cell Lymphoma (MCL)Part I of Living with Mantle Cell Lymphoma
    24. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    25. Progress in the Treatment of Follicular Lymphoma
    26. Updates from the 2020 American Society of Hematology (ASH) Annual Meeting
    27. Update on Diffuse Large B-Cell Lymphoma (DLBCL)
    28. New Perspectives in the Treatment of Peripheral T-Cell Lymphoma (PTCL)
    29. What’s New in the Treatment of Hodgkin Lymphoma
    30. Treatment Update on Mantle Cell Lymphoma (MCL)
    31. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    32. Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
    33. Taking Your Blood Cancer Treatment on Schedule
    34. The Latest News in the Treatment of Waldenstrom’s Macroglobulinemia (WM)
    35. Update on Diffuse Large B-Cell Lymphoma
    36. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    37. The Emerging Role of Immunotherapy in the Treatment of Lymphoma

For Mantle Cell Lymphoma

    1. Update from the 2022 American Society of Hematology (ASH) Annual Meeting
    2. Update On Marginal Zone Lymphoma (MZL)
    3. Waldenstrom’s Macroglobulinemia (WM): Treatment Progress
    4. Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
    5. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    6. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    7. Mantle Cell Lymphoma: Treatment UpdatePart I of Living with Mantle Cell Lymphoma (MCL)
    8. What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
    9. Update from the 2021 American Society of Hematology (ASH) Annual Meeting
    10. Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
    11. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    12. Update on Diffuse Large B-Cell Lymphoma (DLBCL)
    13. Update on CAR T-Cell Therapies
    14. Progress in the Treatment of Waldenstrom’s Macroglobulinemia (WM)
    15. Treatment Update on Mantle Cell Lymphoma (MCL)Part I of Living with Mantle Cell Lymphoma
    16. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    17. Updates from the 2020 American Society of Hematology (ASH) Annual Meeting
    18. Treatment Update on Mantle Cell Lymphoma (MCL)
    19. Update on CAR-T Cell Therapy
    20. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    21. Taking Your Blood Cancer Treatment on Schedule
    22. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    23. The Emerging Role of Immunotherapy in the Treatment of Lymphoma

For Marginal Zone Lymphoma

    1. Diffuse Large B-Cell Lymphoma (DLBCL): Treatment Updates
    2. Update from the 2022 American Society of Hematology (ASH) Annual Meeting
    3. Update On Marginal Zone Lymphoma (MZL)
    4. Waldenstrom’s Macroglobulinemia (WM): Treatment Progress
    5. Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
    6. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    7. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    8. Marginal Zone Lymphoma (MZL): Treatment Updates
    9. What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
    10. Update from the 2021 American Society of Hematology (ASH) Annual Meeting
    11. Update on Marginal Zone Lymphoma (MZL)
    12. Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
    13. Update on Diffuse Large B-Cell Lymphoma (DLBCL)
    14. Update on CAR T-Cell Therapies
    15. Progress in the Treatment of Waldenstrom’s Macroglobulinemia (WM)
    16. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    17. Updates from the 2020 American Society of Hematology (ASH) Annual Meeting
    18. Update on CAR-T Cell Therapy
    19. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    20. Taking Your Blood Cancer Treatment on Schedule
    21. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    22. The Emerging Role of Immunotherapy in the Treatment of Lymphoma

For Melanoma

    1. Highlights from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - "Advancing Equitable Cancer Care Through Innovation"Part II of Highlights from the 2022 ASCO Annual Meeting
    2. People of Color Living with Skin Cancer
    3. Emerging Treatments for Metastatic MelanomaPart II of Living with Advanced Skin Cancer and Melanoma
    4. Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart II of Equity. Every Patient. Every Day. Everywhere.
    5. Emerging Treatments for Metastatic MelanomaPart II of Living with Advanced Skin Cancer and Melanoma
    6. New Perspectives in the Treatment of Advanced Skin Cancer: Advanced Basal Cell and Squamous Cell CancersPart I of Living with Advanced Skin Cancer and Melanoma
    7. Emerging Treatments for Metastatic MelanomaPart II of Life with Advanced Skin Cancer

For Merkel Cell Carcinoma

    1. Emerging Treatments for Metastatic MelanomaPart II of Living with Advanced Skin Cancer and Melanoma
    2. Treatment Perspectives on Merkel Cell Carcinoma (MCC)Part I of Living with Merkel Cell Carcinoma (MCC)

For Mesothelioma

    1. Mesothelioma: Innovative Treatment Options
    2. Mesothelioma: Innovative Treatment Options
    3. Advances in the Treatment of Mesothelioma

For Metastatic Breast Cancer

    1. Updates from the 45th Annual San Antonio Breast Cancer Symposium on Triple Negative Breast Cancer
    2. Living with Breast Cancer – Updates from the 45th San Antonio Breast Cancer Symposium (SABCS)Part I of Living with Breast Cancer – Updates from the 45th Annual San Antonio Breast Cancer Symposium (SABCS)
    3. Metastatic Triple Negative Breast CancerPart I of Living with Metastatic Triple Negative Breast Cancer
    4. Metastatic Breast Cancer: Treatment Updates
    5. HER2-Positive Metastatic Breast Cancer: What’s New in Treatment & Quality-of-Life
    6. The Role of Radiation Therapy in the Treatment of Breast Cancer
    7. Metastatic Breast Cancer in African Americans: New Treatments
    8. Updates in the Treatment of Estrogen Receptor (ER) Positive, Progesterone Receptor (PR) Positive and HER2 Positive Breast Cancer from the San Antonio Breast Cancer Symposium (SABCS)Part II of Living with Breast Cancer, with Updates from the San Antonio Breast Cancer Symposium (SABCS)
    9. Updates from the 44th Annual San Antonio Breast Cancer Symposium (SABCS) on Triple Negative Breast Cancer (TNBC)
    10. The Latest Developments Reported at the 44th Annual San Antonio Breast Cancer Symposium (SABCS)Part I of Living with Breast Cancer, with Updates from the San Antonio Breast Cancer Symposium (SABCS)
    11. HER2-Positive Metastatic Breast Cancer: New Therapies
    12. Metastatic Breast Cancer: Treatment Updates
    13. Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart I of Equity. Every Patient. Every Day. Everywhere.
    14. Updates on the Treatment of Estrogen Receptor (ER) Positive, Progesterone Receptor (PR) Positive & HER2 Positive Breast Cancer from the 43rd Annual San Antonio Breast Cancer Symposium (SABCS)Part II of Life with Breast Cancer - Updates from the 43rd Annual San Antonio Breast Cancer Symposium (SABCS)
    15. The Latest Developments Reported from the 43rd Annual San Antonio Breast Cancer Symposium (SABCS)Part I of Life with Breast Cancer - Updates from the 43rd Annual San Antonio Breast Cancer Symposium (SABCS)
    16. Updates from the San Antonio Breast Cancer Symposium (SABCS) on Triple Negative Breast Cancer (TNBC)
    17. Highlights from the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting: Unite and Conquer: Accelerating Progress TogetherPart I of Your Guide to the Latest Cancer Research and Treatment
    18. Triple Negative Breast Cancer and African American Women
    19. What’s New in the Treatment of Breast Cancer for Women of All Ages
    20. What’s New in the Treatment of Metastatic Breast Cancer

For Multiple Myeloma

    1. Update from the 2022 American Society of Hematology (ASH) Annual Meeting
    2. Progress in the Treatment of Multiple Myeloma
    3. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    4. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    5. Coping with the Stresses of Caregiving When Your Loved One Has Multiple MyelomaPart II of Living with Multiple Myeloma
    6. What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
    7. Progress in the Treatment of Multiple MyelomaPart I of Living with Multiple Myeloma
    8. Update from the 2021 American Society of Hematology (ASH) Annual Meeting
    9. Transplantation as a Treatment Option for Blood Cancers
    10. Update on CAR T-Cell Therapies
    11. Progress in the Treatment of Multiple Myeloma
    12. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    13. Updates from the 2020 American Society of Hematology (ASH) Annual Meeting
    14. Progress in the Treatment of Multiple MyelomaPart I of Life with Multiple Myeloma
    15. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    16. Taking Your Blood Cancer Treatment on Schedule
    17. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches

For Myelodysplastic Syndromes

    1. Progress in the Treatment of Myelodysplastic Syndromes (MDS)
    2. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    3. What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
    4. Update from the 2021 American Society of Hematology (ASH) Annual Meeting
    5. Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart II of Equity. Every Patient. Every Day. Everywhere.
    6. Transplantation as a Treatment Option for Blood Cancers
    7. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    8. Update on CAR T-Cell Therapies
    9. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    10. Updates from the 2020 American Society of Hematology (ASH) Annual Meeting
    11. Progress in the Treatment of Myelodysplastic Syndrome (MDS)
    12. Taking Your Blood Cancer Treatment on Schedule

For Myelofibrosis

    1. What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
    2. Transplantation as a Treatment Option for Blood Cancers
    3. Progress in the Treatment of Myelofibrosis
    4. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    5. Update on CAR T-Cell Therapies
    6. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    7. Updates from the 2020 American Society of Hematology (ASH) Annual Meeting
    8. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    9. Taking Your Blood Cancer Treatment on Schedule
    10. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches

For Myeloproliferative Neoplasms

    1. Update from the 2022 American Society of Hematology (ASH) Annual Meeting
    2. Chronic Lymphocytic Leukemia (CLL): Treatment Updates
    3. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    4. What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
    5. Update from the 2021 American Society of Hematology (ASH) Annual Meeting
    6. Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart II of Equity. Every Patient. Every Day. Everywhere.
    7. Transplantation as a Treatment Option for Blood Cancers
    8. Progress in the Treatment of Myelofibrosis
    9. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    10. Update on CAR T-Cell Therapies
    11. Progress in the Treatment of Waldenstrom’s Macroglobulinemia (WM)
    12. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    13. Updates from the 2020 American Society of Hematology (ASH) Annual Meeting
    14. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    15. Taking Your Blood Cancer Treatment on Schedule
    16. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches

For Non-Hodgkin Lymphoma

    1. Diffuse Large B-Cell Lymphoma (DLBCL): Treatment Updates
    2. Update from the 2022 American Society of Hematology (ASH) Annual Meeting
    3. Update On Marginal Zone Lymphoma (MZL)
    4. Waldenstrom’s Macroglobulinemia (WM): Treatment Progress
    5. Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
    6. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    7. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    8. What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
    9. Update from the 2021 American Society of Hematology (ASH) Annual Meeting
    10. Transplantation as a Treatment Option for Blood Cancers
    11. Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
    12. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    13. Update on CAR T-Cell Therapies
    14. Progress in the Treatment of Waldenstrom’s Macroglobulinemia (WM)
    15. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    16. Progress in the Treatment of Follicular Lymphoma
    17. Updates from the 2020 American Society of Hematology (ASH) Annual Meeting
    18. Update on CAR-T Cell Therapy
    19. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    20. Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
    21. Taking Your Blood Cancer Treatment on Schedule
    22. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    23. The Emerging Role of Immunotherapy in the Treatment of Lymphoma

For Ovarian Cancer

    1. Ovarian Cancer: Treatment Updates
    2. Highlights from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting – “Advancing Equitable Cancer Care Through Innovation"Part I of Highlights from the 2022 ASCO Annual Meeting
    3. Ovarian Cancer: Treatment Updates
    4. Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart I of Equity. Every Patient. Every Day. Everywhere.
    5. Medical Update on Ovarian Cancer
    6. Highlights from the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting: Unite and Conquer: Accelerating Progress TogetherPart I of Your Guide to the Latest Cancer Research and Treatment

For Pancreatic Cancer

    1. Highlights from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - "Advancing Equitable Cancer Care Through Innovation"Part II of Highlights from the 2022 ASCO Annual Meeting
    2. Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart II of Equity. Every Patient. Every Day. Everywhere.
    3. Treatment Update on Pancreatic Cancer

For Peripheral T-Cell Lymphoma

    1. Diffuse Large B-Cell Lymphoma (DLBCL): Treatment Updates
    2. Update from the 2022 American Society of Hematology (ASH) Annual Meeting
    3. Update On Marginal Zone Lymphoma (MZL)
    4. Waldenstrom’s Macroglobulinemia (WM): Treatment Progress
    5. Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
    6. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    7. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    8. What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
    9. Update from the 2021 American Society of Hematology (ASH) Annual Meeting
    10. Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
    11. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    12. Update on Diffuse Large B-Cell Lymphoma (DLBCL)
    13. Update on CAR T-Cell Therapies
    14. Progress in the Treatment of Waldenstrom’s Macroglobulinemia (WM)
    15. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    16. Updates from the 2020 American Society of Hematology (ASH) Annual Meeting
    17. New Perspectives in the Treatment of Peripheral T-Cell Lymphoma (PTCL)
    18. Update on CAR-T Cell Therapy
    19. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches